APM
CHRS icon

Avidity Partners Management’s Coherus Oncology CHRS Stock Holding History

Avidity Partners Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,023,500
Closed -$18.3M – 73
2020
Q2 		$18.3M Buy
1,023,500
+641,500
+168% +$10.9M 1.17% 34
2020
Q1 		$6.2M Buy
382,000
+167,500
+78% +$3.09M 0.86% 44
2019
Q4 		$3.86M Buy
+214,500
New +$3.96M 2.43% 21

Other funds holding CHRS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Kohlberg Kravis Roberts & Co
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Avidity Partners Management's CHRS Position: Q3 2020 in Review

Avidity Partners Management sold out of Coherus Oncology (CHRS) in Q3 2020, closing a stake of 1,023,500 shares — an estimated $18.3M sold.

Avidity Partners Management first reported a position in CHRS in Q4 2019 and held it in 3 quarters. The position peaked at $18.3M in Q2 2020. 201 funds tracked by Wall St. Rank hold CHRS as of Q3 2020.

  • Avidity Partners Management reported no remaining Coherus Oncology position as of Q3 2020 after selling out during the quarter.
  • Avidity Partners Management sold 1,023,500 Coherus Oncology shares in Q3 2020, an estimated $18.3M.
  • Avidity Partners Management first reported a position in Coherus Oncology in Q4 2019 and held it in 3 quarters.
  • Avidity Partners Management's Coherus Oncology position peaked at $18.3M in Q2 2020.
  • 201 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2020.

Based on Avidity Partners Management's 13F filing for Q3 2020, filed 16 Nov 2020.